Despite the fact that there are no clinical trials currently underway to investigate the effects of TNF inhibitors in PAH, and considering the relatively safe profile of this treatment approach, it is indeed a potential target for investigation in the near future. Here, TNF is linked to pulmonary arterial hypertension.